Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

Intellia Therapeutics (NTLA) will present at the Jefferies Global Healthcare Conference in London on November 17, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Intellia Therapeutics (NTLA) will present at the Jefferies Global Healthcare Conference in London on November 17, 2026.

The presentation is scheduled for 8:30 a.m. GMT / 3:30 a.m. ET. A live webcast will be available on the Events page in the Investors & Media section of Intellia’s website, with a replay available for approximately 90 days.

Argus 15 min delay 62 alerts

-7.89% vs previous close $11.16 last price 1.3x rel. volume Open Argus

Details

Market move: NTLA -7.89% vs previous close. healthcare conference presentation

$10.96 – $12.24 Day Range

$1.57B Mkt Cap at Last Price

On Nov 10, the day this news came out, the latest delayed price for NTLA is 7.89% below the previous close. Our momentum scanner has recorded 62 alerts for this stock so far that day. The latest delayed price is $11.15.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

crispr gene editing

1 terms

crispr gene editing technical

"leveraging CRISPR gene editing and other core technologies"

CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/10/2026 - 08:00 AM EST

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 8:30 a.m. GMT / 3:30 a.m. ET.

A live webcast will be available on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com